Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.57 |
| ▸ | ACACA | Q13085 | 11/20 | 0.57 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305724 | 0.99 | ACACB (0.56) | ACACBACACAL3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL4295709 | 0.92 | ACACB (0.69) | ACACBACACAL3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL4298140 | 0.88 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL4292053 | 0.84 | ACACB (0.69) | ACACBACACA | |
| SCHEMBL4289525 | 0.82 | ACACB (0.52) | ACACBACACAMAPK1 | |
| SCHEMBL13980048 | 0.82 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL4289538 | 0.80 | ACACB (0.80) | ACACBACACA | |
| SCHEMBL6183505 | 0.80 | ACACB (0.84) | ACACBACACAL3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL13969593 | 0.80 | HPGD (0.54) | ACACBMAPK1 | |
| SCHEMBL4298078 | 0.80 | ACACB (0.82) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | ACACB 23/4885ACACA 12/4885L3MBTL3 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.